Class Matters: Sensitivity of BRAF-Mutant Melanoma to MAPK Inhibition

Mutations in BRAF outside of the 600 codons (BRAF non- V600) occur across cancer types, including in 3% to 5% of melanomas. The optimal treatment strategies are not clear but based on preclinical studies could include MEK inhibitors. Combining BRAF and MEK inhibitors in this population may provide additional benefit. See related article by Dankner et al., p. 6483